reviewNew England Journal of MedicineSep 30, 2020Closed access

Myelodysplastic Syndromes

MCMario Cazzola

University of Pavia · Policlinico San Matteo Fondazione

PubMed
Indexed incrossrefpubmed

Abstract

MDS are clonal hematopoietic disorders involving morphologic defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid leukemia. Except for del(5q) MDS, which is responsive to lenalidomide, these disorders are largely managed with supportive care.

Citation impact

478
total citations
FWCI
36.77
Percentile
100%
References
99
Citations per year

Authors

1

Topics & keywords

Topics
Keywords
  • Lenalidomide
  • Myelodysplastic syndromes
  • Myeloid leukemia
  • Medicine
  • Haematopoiesis
  • Peripheral blood
  • Leukemia
  • Immunology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.